Statistics from Altmetric.com
More than a decade of use of the anti-tumour necrosis factor (anti-TNF) agents in rheumatology has confirmed their acceptable safety profile and very few new rare side effects have emerged. However, TNFα, a pleiotropic cytokine, is important to many physiological functions and its suppression may lead to unexpected consequences. We describe here a rare case of reversible oligoasthenozoospermia in a young patient.
This case concerns a 35-year-old father of a healthy 4-year-old child who was successfully treated for 3 years with adalimumab, a monoclonal human antibody against TNFα, 40 mg subcutaneously every 2 weeks for ankylosing spondylitis (AS). The therapy …
Competing interests None.
Ethics approval This letter reports a case of an ankylosing spondylitis patient treated according to the current guidelines. Personal data remain completely anonymous.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.